Veronika Nesterova

Ms. Veronika Nesterova

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AGArtem Gureev
Artem Gureev
ISIrina S. Sadovnikova
Irina S. Sadovnikova
KCKate Chernyshova
Kate Chernyshova
ATArina D. Tsvetkova
Arina D. Tsvetkova
PBPolina I. Babenkova
Polina I. Babenkova
Egor PlotnikovEgor Plotnikov
Egor Plotnikov
The consequences of stroke include cognitive deficits and sensorimotor disturbances, which are largely related to mitochondrial impairments in the brain. In this work, we have shown that the mimetic of the ketogenic diet beta-hydroxybutyrate (βHB) can improve neurological brain function in stroke. At 3 weeks after photothrombotic stroke, mice receiving βHB with drinking water before and after surgery recovered faster in terms of sensorimotor functions assessed by the string test and static rods and cognitive functions assessed by the Morris water maze. At the same time, the βHB-treated mice had lower expression of some markers of astrocyte activation and inflammation (Gfap, Il-1b, Tnf). We hypothesize that long-term administration of βHB promotes the activation of the nuclear factor erythroid 2-related factor 2/antioxidant response element (Nrf2/ARE) pathway, which leads to increased expression of antioxidant genes targeting mitochondria and genes involved in signaling pathways necessary for the maintenance of synaptic plasticity. βHB partially maintained mitochondrial DNA (mtDNA) integrity during the first days after photothrombosis. However, in the following three weeks, the number of mtDNA damages increased in all experimental groups, which coincided with a decrease in Ogg1 expression, which plays an important role in mtDNA repair. Thus, we can assume that βHB is not only an important metabolite that provides additional energy to brain tissue during recovery from stroke under conditions of mitochondrial damage but also an important signaling molecule that supports neuronal plasticity and reduces neuroinflammation.

Verified
Journal Article
Open access
PDF file
AGArtem Gureev
Artem Gureev
VNVeronika Nesterova
Veronika Nesterova
PBPolina I. Babenkova
Polina I. Babenkova
MIMikhail Ivanov
Mikhail Ivanov
Egor PlotnikovEgor Plotnikov
Egor Plotnikov
Denis N. SilachevDenis N. Silachev
Denis N. Silachev
Traumatic brain injuries (TBIs) are a serious problem affecting individuals of all ages. Mitochondrial dysfunctions represent a significant form of secondary injury and may serve as a promising target for therapeutic intervention. Our research demonstrated that craniotomy, which precedes the experimental induction of trauma in mice, can cause considerable damage to mitochondrial DNA (mtDNA), disrupt the regulatory expression of angiogenesis, and increase inflammation. However, the reduction in the mtDNA copy number and glial activation occur only after a direct impact to the brain. We explored two potential therapeutic agents: the dietary supplement L-carnitine—a potential reserve source of ATP for the brain—and the cardiac drug mildronate, which inhibits L-carnitine but activates alternative compensatory pathways for the brain to adapt to metabolic disturbances. We found that L-carnitine injections could protect against mtDNA depletion by promoting mitochondrial biogenesis. However, they also appeared to aggravate inflammatory responses, likely due to changes in the composition of the gut microbiome. On the other hand, mildronate enhanced the expression of genes related to angiogenesis while also reducing local and systemic inflammation. Therefore, both compounds, despite their opposing metabolic effects, have the potential to be used in the treatment of secondary injuries caused by TBI.

17 November 2025 in Exploration of Neuroprotective Therapy
Verified
Journal Article
Open access
PDF file
EKEkaterina P. Krutskikh
Ekaterina P. Krutskikh
PBPolina Babenkova
Polina Babenkova
VNVeronika Nesterova
Veronika Nesterova
ATArina D. Tsvetkova
Arina D. Tsvetkova
IBInna Burakova
Inna Burakova
AGArtem Gureev
Artem Gureev
Aim: Systemic inflammation is a key factor in cognitive decline and neurodegenerative diseases. Polyphenols, such as curcumin, resveratrol, and salidroside, exhibit neuroprotective effects, but their low bioavailability raises questions about their mechanism of action. The gut-brain axis, mediated by microbiome modulation, may play a critical role in their cognitive benefits. This study investigated whether polyphenols (curcumin, resveratrol, and salidroside) improve cognitive function in mice with lipopolysaccharide (LPS)-induced gut inflammation by modulating the gut microbiome and reducing neuroinflammation. Methods: C57BL/6 mice were divided into five groups: control, LPS, and LPS + polyphenol treatments (curcumin, resveratrol, or salidroside). LPS was administered intraperitoneally to induce inflammation, while polyphenols were given orally for three weeks. Cognitive performance was assessed using the Morris water maze. Gut microbiome composition (16S rRNA sequencing), mitochondrial DNA (mtDNA) damage, and gene expression in brain regions were analyzed. Results: LPS impaired spatial memory, but resveratrol and salidroside significantly mitigated these deficits. Polyphenols restored beneficial bacteria (e.g., Alloprevotella, Eubacterium) and suppressed pathogenic taxa (e.g., Peptostreptococcales). They also reduced pro-inflammatory markers in the cortex and hippocampus. Curcumin showed weaker effects. No significant mtDNA damage was detected. Conclusions: Polyphenols, particularly resveratrol and salidroside, improve cognition during systemic inflammation by remodeling the gut microbiome and attenuating neuroinflammation. These findings highlight the gut-brain axis as a therapeutic target for inflammation-driven cognitive disorders.

5 December 2023 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
AGArtem Gureev
Artem Gureev
PBPolina I. Babenkova
Polina I. Babenkova
VNVeronika Nesterova
Veronika Nesterova
ATArina D. Tsvetkova
Arina D. Tsvetkova
MGMariya Vladimirovna Gryaznova
Mariya Vladimirovna Gryaznova
ESEkaterina A. Shaforostova
Ekaterina A. Shaforostova
L-carnitine plays a critical role in sperm functioning and maintaining male fertility. Mildronate is a widely used drug for treating cardiovascular diseases. Mildronate inhibits L-carnitine biosynthesis and transport into cells while increasing glucose supply. Therefore, it is speculated that mildronate may impair male fertility by depleting L-carnitine. On the other hand, mildronate is known to have anti-inflammatory effects, which can positively influence the male reproductive system in certain physiological conditions. In this study, we induced inflammation in mice through lipopolysaccharide (LPS) injections and examined some inflammation markers in the testes and intestine, which contribute significantly to the development of systemic inflammation. We demonstrated that mildronate reduces inflammation in mouse testes and preserves mitochondrial DNA integrity. Importantly, mildronate-induced L-carnitine depletion did not have a negative impact on testicular properties or sperm count. We propose that the anti-inflammatory effect of mildronate may be linked to its action on the bacterial composition of the gut microbiome. Mildronate increases the Firmicutes/Bacteroidetes ratio, which is reduced after LPS injections. In contrast to L-carnitine supplementation, mildronate does not decrease the level of Alloprevotella, a bacterial genus that is necessary for reducing inflammation. Additionally, mildronate decreased the expression of pro-inflammatory cytokines and inflammation markers in the intestine, which aligns with our hypothesis regarding its anti-inflammatory effect.

29 September 2026 in Current Neuropharmacology
Verified
Journal Article
Closed access
PDF file
VNVeronika Nesterova
Veronika Nesterova
DADianna Adzhemian
Dianna Adzhemian
VGViktoria Gribovskaya
Viktoria Gribovskaya
PBPolina Babenkova
Polina Babenkova
MIMikhail Ivanov
Mikhail Ivanov
Denis N. SilachevDenis N. Silachev
Denis N. Silachev
Introduction: Traumatic brain injury (TBI) frequently results in persistent cognitive deficits driven by secondary mechanisms including mitochondrial dysfunction, oxidative stress, and neuroinflammation. We compared the effects of L-carnitine and mildronate on spatial memory recovery after TBI and investigated the underlying cellular mechanisms. Methods: Male C57BL/6 mice were subjected to controlled cortical impact TBI and assigned to naïve, sham, TBI+saline, TBI+mildronate (100 mg/kg/day), or TBI+L-carnitine groups. Spatial working memory was evaluated using the Morris water maze over 21 days. At 24 days post-injury, we measured cortical and hippocampal malondialdehyde (MDA), mtDNA integrity and copy number, expression of genes related to mitochondrial biogenesis, glucose metabolism, angiogenesis, and neuroinflammation, and performed blood cytology. Results: TBI induced significant memory deficits, elevated MDA, and reduced mtDNA copy number without increased damage. Mildronate, but not L-carnitine, significantly improved cognitive performance. Mildronate upregulated Tfam, Glut4, Cd34, and Eng while downregulating Gfap in the hippocampus. Both compounds decreased MDA and circulating cell-free mtDNA. Discussion: Mildronate’s superior neuroprotection appears to involve enhanced mitochondrial biogenesis, glucose transport, and angiogenesis, alongside suppression of astrogliosis. In contrast, L-carnitine showed limited cognitive benefit, possibly due to insufficient mitochondrial renewal and vascular repair. Conclusion: Mildronate exerts greater neuroprotective effects than L-carnitine after TBI, likely via coordinated restoration of mitochondrial quality control, glucose utilization, and vascular remodeling, offering a promising strategy to mitigate post-traumatic cognitive decline.

Verified
Journal Article
Open access
PDF file
VGViktoria Gribovskaya
Viktoria Gribovskaya
DADianna Adzhemian
Dianna Adzhemian
PRPavel Denisovich Rogozin
Pavel Denisovich Rogozin
VNVeronika Nesterova
Veronika Nesterova
AGArtem Gureev
Artem Gureev
Denis N. SilachevDenis N. Silachev
Denis N. Silachev
Many widely used open-head models of traumatic brain injury (TBI) require craniotomy before injury, while sham-operated animals undergo surgery without impact and serve as controls. However, sham surgery itself may alter physiological, molecular, and behavioral parameters, complicating interpretation of TBI-specific effects. This narrative review, based on a structured PubMed search, synthesizes studies employing a three-group design to distinguish injury-related changes from those associated with craniotomy and other perioperative procedures. Evidence indicates that sham surgery produces outcome-, region-, and time-dependent effects that are generally milder, more localized, and more transient than TBI. These include neuroinflammatory responses, localized neuronal alterations, temporary sensorimotor and cognitive deficits, nociceptive changes, and shifts in gut microbiota. In contrast, TBI causes more severe abnormalities, including extensive neuronal damage, sustained astrogliosis, microglial activation, neutrophilic infiltration, mitochondrial dysfunction, and long-term dysbiosis. Most electrophysiological parameters are relatively unaffected by sham surgery, although selected changes have been reported. Importantly, differences between naïve and sham animals cannot be attributed exclusively to craniotomy, as anesthesia, analgesia, and surgical technique may contribute. Thus, sham surgery should not be considered a biologically neutral control. Inclusion of both naïve and sham groups is particularly important when distinguishing surgery-associated from injury-specific effects in preclinical studies.